Amador Bioscience Upgrades Full-Range Laboratory Testing Capabilities to Empower Clinical Development and Become Clients’ Preferred CRO

Striving to become the person you aspire to be is not only a hope for life but also the genuine sentiment of Dr. Zeng Rong after transitioning from the client side to the service provider side.

Dr. Rong Zeng is the Co-Founder and President of Amador Bioscience, a global contract research organization (CRO) specializing in translational and clinical development with operations in China, the United States, and the European Union. He also serves as the CEO of Amador Bioscience China. Prior to joining Amador Bioscience, Dr. Zeng accumulated over 20 years of experience in immunology research and biologics drug development at renowned international pharmaceutical companies such as AstraZeneca. Having engaged extensively with numerous pharmaceutical CROs, he gained firsthand insight from the sponsor’s perspective into the extensive requirements and expectations that pharmaceutical companies place on CRO partners. Since joining Amador Bioscience to lead its CRO services, Dr. Zeng has guided his team to evolve into the ideal partner—one that fulfills the highest standards expected by both the industry and sponsors alike.

Dr. Zeng Rong, Co-founder and President of Amador Bioscience (CN, USA, EU), and CEO of Amador China

What Kind of CRO Do Pharmaceutical Companies “Prefer” Most? Dr. Zeng Rong Shares His Insights: First,Sufficiently Professional Technical Background, to determine whether it has the capacity to undertake orders; secondly,Sufficiently Rich Experience Accumulation, which determines the level of proficiency in resolving complex and challenging issues; thirdly,International Standards for Quality and Compliance, to ensure compliance with global drug registration and filing requirements; fourthly,Excellent team service orientation and communication skills, which meets customer needs and affects the efficiency and outcomes of the entire collaboration.

It is no exaggeration to say that AMADOR BIOSCIENCE excels in all four of these areas. Under the leadership of Dr. Zeng Rong, its laboratory testing services—particularly in bioanalysis—have achieved exceptionally high customer satisfaction and retention rates, with zero complaints or adverse incidents recorded. As one pharmaceutical client previously partnered with AMADOR BIOSCIENCE remarked, “AMADOR BIOSCIENCE delivers work that is both fast and high-quality!” This partner also referred other pharmaceutical industry friends to outsource their R&D projects to AMADOR BIOSCIENCE. It is precisely this word-of-mouth reputation that has ensured a steady stream of business orders for AMADOR BIOSCIENCE since its establishment four years ago.

In June 2022, AMADOR BIOSCIENCE officially inaugurated its newly upgraded headquarters at the Kaifeng Technology Park in Xiaoshan District, Hangzhou, China, signaling a comprehensive enhancement of the company’s business capacity in the Chinese market. It is reported thatThe newly commissioned building of Amador Bioscience spans a total area of 6,400 square meters, of whichMore than half areLaboratory。

Laboratory testing services constitute one of the three core business segments of Amador Bioscience. The company’s other two complementary businesses are clinical pharmacology and clinical development. Laboratory testing not only independently provides bioanalytical services to pharmaceutical companies—covering large molecules, small molecules, gene therapy, and cell therapy—but also collaborates with the company’s clinical pharmacology and clinical development services to deliver more comprehensive, integrated solutions, thereby enhancing drug R&D efficiency.

The comprehensive upgrade of the laboratory has not only significantly expanded the facility space but also enhanced the company’s technical hardware infrastructure and supporting facilities, such asThe MSD S600 with high sensitivity for immunoassays, the Cytek NL-2000 and BD FACSLyric capable of flow cytometry analysis, and the latest-generation instruments such as the SCIEX 6500+ that provides mass spectrometry detection., enabling AMADOR BIOSCIENCE to achieve a significant leap in both the volume and quality of business engagements.

From a single laboratory at its inception to an entire building today, the transformation of Amador Bioscience has been profoundly felt by Dr. Zeng Rong, Head of Laboratory Testing Services and a founding team member. “In the past, limited laboratory conditions constrained the scope of services we could offer. For instance, with qPCR testing, non-specific interference from the laboratory environment often led to acceptable but highly variable results. Now, Amador Bioscience’s new laboratory is designed, constructed, and fitted out in strict accordance with international top-tier standards. Using the same testing methods, the new facility—with its precisely controlled environment and ample independent space—delivers superior testing parameters.”

For the laboratory testing services industry, the key differentiator is not solely the quality of laboratory instruments and equipment; the design of testing methodologies and data interpretation are also critical. Differences in laboratory instruments define the capability boundaries—determining what can and cannot be tested—but such disparities among peers can be bridged through capital investment in the latest equipment. However, for pharmaceutical companies conducting laboratory testing,The fundamental need is not merely to obtain data read from instruments, but rather to elucidate the meaning of the data and uncover hidden issues through well-designed methodologies and data interpretation, thereby providing practical and actionable recommendations and support for the clinical development and regulatory submission of pharmaceutical products.。

This is precisely where AMADOR BIOSCIENCE excels. To borrow Dr. Zeng Rong’s apt description, AMADOR BIOSCIENCENot Just a “Construction Crew,” but Also a “Design Institute”. In collaboration with the sponsor, the laboratory formulates testing strategies, develops and validates corresponding analytical methods, and generates data. By working closely with clinical pharmacology and clinical development teams to interpret data and prepare reports, AMADOR BIOSCIENCE ensures that its technical reports can be directly used as submission materials for new drug marketing applications. This capability heavily relies on the team’s expertise in data analysis and interpretation. The laboratory experts at AMADOR BIOSCIENCE each possess over 10 years of experience in bioanalysis, enabling them to accurately identify the underlying issues reflected by the data and provide valuable guidance for clinical drug development.

As a global translational and clinical development CRO, Amador Bioscience initially focused on specialized areas such as clinical pharmacology and bioanalysis. With years of development, enhanced laboratory facilities, and the ability to meet diverse market demands, Amador Bioscience’s bioanalysis business has gradually established four major technology platforms:Immunodetection Platform, Mass Spectrometry Detection Platform, Cell-Based Detection Platform, Nucleic Acid Detection Platform。

Among these, the immunoassay platform, also known as the ligand-binding assay platform, is established based on the specificity of antigen-antibody interactions. It is primarily used for macromolecular bioanalysis and biomarker detection, including pharmacokinetics (PK) assays, pharmacodynamics (PD) assays, and immunogenicity assessments. Dr. Zeng Rong has participated in the drafting of industry guidelines in this field. The mass spectrometry platform is mainly used for PK and PD assays of small molecules and antibody-drug conjugates (ADCs). The cell-based assay platform primarily involves measuring changes in immune cell parameters post-dosing, assessing the relationship between drug dosage and receptor occupancy (RO), and conducting PK assays for CAR-T cell therapies. Nucleic acid testing is primarily used to support the development of gene therapies.

After stabilizing its core business, AMADOR BIOSCIENCE has continuously developed emerging testing services while adapting to market and customer demands. “Looking toward the future, as a support department, we provide additional services in translational medicine and clinical laboratory testing based on new customer needs,” explained Dr. Zeng Rong. “For example, in translational medicine, we leverage biomarker testing to help innovative pharmaceutical companies ‘select dosages, identify patient populations, and determine indications.’ Currently, AMADOR is capable of providing comprehensive biomarker testing services.”

From a long-term perspective, Amador Bioscience has begun to establish central laboratory services. These services not only cover core businesses such as bioanalysis and biomarkers but also assist pharmaceutical companies with sample management, data management, and investigator support. By embracing innovative technologies, Amador Bioscience is positioning itself at the forefront of new drug development.

While CROs are commonly perceived as labor-intensive contract manufacturing facilities, AMADOR BIOSCIENCE aims to shatter this stereotype by leveraging technology empowerment to become the “smartest brain” of the pharmaceutical industry.

Dr. Zeng Rong emphasized that such positioning places extremely high demands on the team’s capabilities. When recruiting, the company not only evaluates individual qualifications but also prioritizes candidates with the courage and determination to “tackle the toughest challenges.” This approach has gradually helped build a culture at AMADOR BIOSCIENCETeam spirit in helping clients solve challenging problems“Do what others cannot do, and solve problems that others cannot solve. It is often the thorny issues without standard answers that require us to have the courage to tackle them head-on.”

During the interview, Dr. Zeng Rong repeatedly mentioned TSMC, a company he greatly respects. As a global leader in professional integrated circuit manufacturing services, TSMC has grown from its foundry origins to capture over 50% of the global market share. “Although we operate in different industries, TSMC’s spirit of pursuing product excellence is always worth learning from,” stated Dr. Zeng Rong. “TSMC truly makes significant contributions to society and the industry. While becoming a world-leading chip manufacturer is easier said than done, AMADOR BIOSCIENCE has been consistently striving toward this goal in the long run.”

Meanwhile, AMADOR BIOSCIENCE’s laboratory also aims to collaborate with research institutes to jointly develop cutting-edge testing technologies, truly establishing itself as a technology-driven CRO.